In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Science

Volumn 303, Issue 5659, 2004, Pages 844-848

  Vassilev, Lyubomir T ^a   Vu, Binh T ^a   Graves, Bradford ^a   Carvajal, Daisy ^a   Podlaski, Frank ^a   Filipovic, Zoran ^a   Kong, Norman ^a   Kammlott, Ursula ^a   Lukacs, Christine ^a   Klein, Christian ^b   Fotouhi, Nader ^a   Liu, Emily A ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL STRUCTURE; GROWTH KINETICS; ONCOLOGY; TUMORS;

APOPTOSIS; CELL CYCLE;

PROTEINS;

ANTINEOPLASTIC AGENT; NUTLIN 1; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

TUMOR;

ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MODULATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; BINDING SITES; CELL CYCLE; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENES, P53; HUMANS; HYDROPHOBICITY; IMIDAZOLES; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR WEIGHT; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; NUCLEAR PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; STEREOISOMERISM; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS MUSCULUS;

EID: 10744221485     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1092472     Document Type: Article

References (31)

1. B. Vogelstein, D. Lane, A. J. Levine, Nature 408, 307 (2000).
2. A. J. Levine, Cell 88, 323 (1997).
3. M. Hollstein, D. Sidransky, B. Vogelstein, C. C. Harris, Science 253, 49 (1991).
4. J. Oliner, K. W. Kinzler, P. S. Meltzer, D. L. George, B. Vogelstein, Nature 358, 80 (1992).
5. X. Wu, J. H. Bayte, D. Olson, A. J. Levine, Genes Dev. 7, 1126 (1993).
6. J. D. Oliner et al., Nature 362, 857 (1993).
7. S. Picksley, D. Lane, Bioessays 15, 689 (1993).
8. M. Ashkroft, K. Vousden, Oncogene 18, 7637 (1999).
9. D. Michael, M. Oren, Semin. Cancer Biol. 13, 49 (2003).
10. J. Momand, D. Jung, S. Wilczynski, J. Niland, Nucleic Acids Res. 26, 3453 (1998).
11. D. Freedman, A. J. Levine, Cell. Mol. Life Sci. 5, 96 (1999).
12. D. Lane, Br. J. Cancer 80, 1 (1999).
13. P. Chene, Nature Rev. Cancer 3, 102 (2003).
14. A. Bottger et al., Curr. Biol. 7, 860 (1997).
15. L. Chen, S. Agrawal, W. Zhou, R. Zhang, J. Chen, Proc. Natl. Acad. Sci. U.S.A. 95, 195 (1998).
16. C. Wasylyk et al., Oncogene 18, 1921 (1999).
17. P. Chene, J. Mol. Biol. 299, 245 (2000).
18. G. Tortora et al., Int. J. Cancer 88, 804 (2000).
19. R. Zhang, H. Wang, Methods Mol. Med. 85, 205 (2003).
20. P. H. Kussie et al., Science 274, 948 (1996).
21. 33 mutation was introduced to increase surface charge and thus improve the solubility and crystallization properties of the protein.
22. F. Bunz et al., Science 282, 1497 (1998).
23. W. El-Deiry et al., Cell 75, 817 (1993).
24. Cells with mutant pS3 accumulate high levels of transcriptionally inactive protein as a result of their inability to up-regulate MDM2 transcription.
25. L. T. Vassilev, unpublished data.
26. Materials and methods are available as supporting material on Science Online.
27. 50 for two mutant p53 lines (SW480 and MDA-MB-43S) and that for three wild-type p53 lines (HCT116, RKO, and SJSA-1). The compounds reported here showed selectivity in the 11 to 18 range.
28. G. S. Jimenez, S. H. Khan, J. M. Stommel, G. M. Wahl, Oncogene 18, 7656 (1999).
29. A deletion construct of human p53 (p53C312) covering the N-terminal binding site and the central DNA binding domain (residues 1 to 312) but lacking the C-terminal tetramerization domain was used for Biacore binding studies.
30. L. T. Vassilev et al., Anticancer Drug Des. 13, 3S9 (2001).
31. We thank C. Tovar, G. Kaplan, K. Dillon, A. Specian, A. Schutt, C.-M. Liu, B. Felix, Q. Xiang, R. Margolis, W. Qing, K. Frank, H. Butscher, and F. Hesse for providing reagents and experimental help; and D. Emerson, D. Fry, S.-S. So, J. Tilley, J. Roberts, D. Presky, H.-J. Mueller, G. Ju, D. Walker, L. Babiss, and D. Heimbrook for discussions. Coordinates are available from the Protein Data Bank with accession code 1RV1.